Note: This document has been translated from the Japanese original for reference purposes only. and is not intended to solicit an investment in the Company or similar activity. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail. The Company assumes no responsibility for this translation or for direct, indirect, or any other forms of damages arising from the translation.

November 10, 2026
Fuji Pharma Co., Ltd.

Notice Regarding Dividend of Surplus (Dividend Increase)

We hereby inform you that at the Board of Directors meeting held on November 10, 2026, we resolved to distribute dividends with a record date of September 30, 2026, as described below, and to submit this matter to the Annual General Meeting of Shareholders scheduled to be held on December 18, 2026.

Details of Dividend (Yen)

	Resolved Amount	Previously Announced Forecast (Announced on March 19, 2026)	Previous Period Actual (Fiscal Year Ended September 2025)
Record Date	September 30, 2026	September 30, 2026	September 30, 2025
Dividend per Share	29.00	26.00	25.50
Total Dividend Amount	758 million	—	624 million
Effective Date	December 21, 2026	—	December 22, 2025
Dividend Source	Retained earnings	—	Retained earnings

Reason for Revision

Our dividend policy is based on profit distribution in accordance with consolidated business performance, targeting a dividend payout ratio of 30% based on operating profit after taxes excluding special factors, with the aim of providing stable and continuous dividends. As our full-year results for the fiscal year ending September 2026 exceeded initial projections, we have decided to increase the year-end dividend forecast per share by 3.00Yen from the previously announced forecast to 29.00Yen per share, and revise the annual dividend forecast per share upward to 52.00Yen. This represents an increase of 6.50Yen per share compared to the previous fiscal year's actual dividend of 45.50Yen.

(Reference) Breakdown of Annual Dividend (Yen)

	Dividend per Share		
Record Date	**Q2 End**	**Year-End**	**Total**
Current Period Actual (Fiscal Year Ended September 2026)	23.00	29.00	52.00
Previous Period Actual (Fiscal Year Ended September 2025)	20.00	25.50	45.50

For further information, contact
Fuji Pharma Co., Ltd.
Corporate Communication Section, Corporate Planning Department, Corporate Strategy Division
fsk_ir@fujipharma.jp